Odimont-LC Syrup is a combination medication containing Levocetirizine 2.5mg and Montelukast 4mg per 5ml, formulated for the management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as rhinorrhea, sneezing, itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), which play a significant role in the inflammatory cascade of asthma and allergic rhinitis. The synergistic action of these two agents provides effective relief from nasal congestion, sneezing, nasal itching, and bronchoconstriction. Odimont-LC Syrup is indicated for pediatric patients suffering from allergic rhinitis, chronic urticaria, and mild to moderate asthma. The syrup formulation ensures ease of administration and accurate dosing in children. It is generally well-tolerated, with common side effects including headache, somnolence, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and concomitant use with other CNS depressants should be monitored. Odimont-LC Syrup offers a convenient and effective therapeutic option for comprehensive allergy management under medical supervision.